Skip to content
    ANIP
    Earnings call· Jun 2026(Q2 FY26)

    ANI PHARMACEUTICALS Q2 FY26 earnings call ANIP

    Aug 7, 2026 Source

    Executive summary

    ANI Pharmaceuticals Q2 FY26 — Record Revenues and Strong Cortrophin Growth

    ANI Pharmaceuticals delivered a strong second quarter, marked by record revenues and EBITDA, driven by robust performance in its rare disease and generics segments. The company is actively transforming into a leading rare disease player, notably through a significant sales force expansion for Cortrophin Gel in the gout market, which is showing promising early indicators. While full-year Cortrophin guidance was modestly adjusted for first-half performance, the company remains confident in its strategic priorities and expects continued growth and operational leverage in 2027.

    Highlights

    5

    • Record Q2 2026 total revenues of $266 million, up 26% year-over-year.

    • Record Cortrophin Gel net revenues of $117.1 million, up 43% year-over-year and 56% quarter-over-quarter.

    • Record adjusted EBITDA of $71.6 million, up 32% year-over-year.

    • Gout expansion sales force fully operational by end of June, with >95% of new reps generating multiple new cases and >1/3 of prescribers initiating 2+ cases.

    • Full-year 2026 total net revenue guidance reaffirmed at $1.08 billion to $1.14 billion, representing 26% year-over-year growth at midpoint.

    Concerns

    3

    • Cortrophin Gel revenue guidance modestly revised down to $520 million to $540 million (from prior higher expectation) primarily due to H1 2026 results.

    • Non-GAAP gross margin decreased by approximately 230 basis points year-over-year to 62.6% due to product mix.

    • ILUVIEN net revenues decreased 16% year-over-year to $18.7 million due to timing of international shipments.

    Guidance & targets

    12
    CategoryTargetConfidence
    Cortrophin Gel Net Revenue
    $520 million to $540 million
    high materiality
    High
    Cortrophin Gel Net Revenue
    $143 million to $153 million
    medium materiality
    High
    Total Company Net Revenue
    $1.08 billion to $1.14 billion
    high materiality
    High
    Total Company Net Revenue
    modestly higher as compared to second quarter
    medium materiality
    Medium
    Adjusted non-GAAP EBITDA
    $285 million to $300 million
    high materiality
    High
    Adjusted non-GAAP EBITDA
    down sequentially, however higher than the first quarter of 2026 non-GAAP EBITDA
    medium materiality
    Medium
    Adjusted non-GAAP Earnings Per Share
    $9.19 and $9.69
    high materiality
    High
    ILUVIEN Net Revenue
    $78 million to $83 million
    medium materiality
    High
    Adjusted Gross Margin
    between 59.9% and 60.9%
    medium materiality
    High
    Shares Outstanding for non-GAAP diluted EPS
    between 21.5 million and 21.8 million
    low materiality
    High
    U.S. GAAP Effective Tax Rate
    approximately 26% to 28%
    low materiality
    High
    Harmony Biosciences Development Milestone Revenue
    $2 million
    low materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Rare Disease - Cortrophin Gel
    Strong growth driven by existing specialties (rheumatology, nephrology, neurology, ophthalmology, pulmonology). Gout expansion showing strong early demand indicators.
    Sales force expansion: 50% increase to ~180 repsGout expansion operational: End of JuneNew cases initiated (July): Highest month for existing specialtiesNew sales reps generating multiple new cases (gout): >95%Prescribers initiating 2+ new cases (gout): >1/3Compounded annual growth rate (2022-2025): 103%2025 sales: $348 million
    		$117.1 million43%56%—
    Rare Disease - ILUVIEN
    Revenue decline due to timing of international shipments. Full-year guidance remains on track. Top-line results from SYNCHRONICITY trial reported, detailed results expected Q4 2026.
    		$18.7 million-16%——
    Generics
    Growth driven by partner generic launch, new product introductions, and operational outperformance. Strong R&D capabilities.
    New product launches (2026 YTD): 12New product launches (2026 full year target): At least 15CGT filings position: #2 playerRevenue from US-manufactured finished goods: ~95%
    		$99.1 million10%——
    Harmony Biosciences IP Out-licensing
    Revenue recognized from a licensing transaction entered in January. Remaining $2 million development milestone expected in Q3 2026.
    Royalty income on WAKIX sales: $9.7 millionDevelopment milestone revenue: $8 million
    		$17.7 million———

    Operational metrics

    18
    Total Net Revenues
    $266 millionup 26% year over year
    Q2 FY26

    Record second quarter 2026 revenues.

    Adjusted EBITDA
    $71.6 millionup 32% year over year
    Q2 FY26

    Record adjusted EBITDA, above prior expectations.

    Non-GAAP Gross Margin
    62.6%decrease of approximately 230 basis points from prior year
    Q2 FY26
    Non-GAAP Research and Development Expenses
    $14.1 milliondecreased 11% to $14.1 million
    Q2 FY26
    Non-GAAP Selling, General, and Administrative Expenses
    $80.7 millionincreased 20% to $80.7 million
    Q2 FY26
    Adjusted non-GAAP Diluted Earnings Per Share
    $2.21compared to $1.80 per share in the prior year period
    Q2 FY26
    Unrestricted Cash Balance
    $360.2 millionup $74.6 million as compared to the December 31, 2025 balance sheet
    as of June 30, 2026
    Outstanding Debt Principal Value
    $620.9 million
    as of June 30, 2026
    Gross Leverage Ratio
    2.4x
    as of June 30, 2026
    Net Leverage Ratio
    1x
    as of June 30, 2026
    Generics R&D Spend
    high single-digit percentage
    ongoing

    Company continues to deploy this percentage of generics revenue into R&D programs.

    Rare Disease Revenue as % of Total Revenue
    approaching 60%
    FY26

    Reflects the company's transformation into a leading rare disease company.

    ACTH Market Size
    $1.3 billionexpected to grow nearly 30%
    FY26

    Driven by growth in key under-penetrated specialties.

    Cortrophin Gel Addressable Patients
    almost 1 million
    current

    ACTH therapies are vastly underpenetrated in this population.

    Cortrophin Gel Addressable Patients
    750,000
    current

    Significantly under-penetrated.

    Cortrophin Gel Sales Force Headcount
    180increased by 50%
    as of June 2026

    Largest commercial expansion in company history.

    Cortrophin Gel ACTH-Naive Prescribers
    approximately half
    current

    Indicates significant opportunity for market expansion.

    ILUVIEN Addressable Patient Population
    at least 10x the number of patients treated with ILUVIEN today
    long term

    Represents a significant and durable opportunity for value creation.

    Industry KPIs

    2
    MetricValueDetails
    EPS revenue guidanceFY26 Total Net Revenue: $1.08B-$1.14B; FY26 Adjusted non-GAAP EPS: $9.19-$9.69USD
    Business development capacity deal appetiteHealthy balance sheet with capacityUSD

    Deals & partnerships

    1
    Harmony BiosciencesLicensing transaction for intellectual property

    Entered into in January 2026. Recognized revenue based on royalty income on sales of WAKIX and work completed toward development milestones.

    Risks & headwinds

    3
    Product mix shiftQ2 FY26

    Decreased non-GAAP gross margin by approximately 230 basis points year-over-year to 62.6%.

    Timing of international shipments for ILUVIENQ2 FY26

    ILUVIEN net revenues down 16% year-over-year to $18.7 million in Q2 FY26.

    Mitigation: Company remains on track to meet full-year guidance for ILUVIEN, reflecting stronger revenue in the back half of the year.

    Sequential decline in Q3 non-GAAP EBITDAQ3 FY26

    Expected to be down sequentially from Q2 FY26 ($71.6M).

    Mitigation: Driven by lower Harmony milestone recognition ($2M vs $8M in Q2) and full operating expense of gout expansion; expected to achieve leverage on gout expansion with increasing Cortrophin Gel revenues later.

    What to watch in Q3 FY26

    5

    Cortrophin Gout Expansion Revenue Contribution

    Q3 FY26 and Q4 FY26
    CurrentLimited impact in Q2 FY26; strong early demand indicators (95% reps with multiple new cases, 1/3 prescribers with 2+ cases).
    TargetMeasurable revenues in Q3 FY26, robust growth in Q4 FY26.

    Why it matters

    The success of the gout expansion is key to Cortrophin's multi-year growth trajectory and the company's transformation into a rare disease leader.

    As expected and as previously discussed, given the timing of📎 operationalizing our gout expansion, it did not have a meaningful impact on Q2 reported revenues, but we continue to expect measurable revenues in the third quarter and robust growth in the fourth quarter...

    Q&A highlights

    5

    Asked for more detail on gout uptake, confidence in Q4 step-up, and penetration levels in existing Cortrophin indications.

    Management highlighted positive leading indicators for gout expansion (95% reps with multiple new cases, 1/3 prescribers with 2+ cases, balanced demand). Explained Q4 step-up due to full impact of 3x larger sales force expansion compared to prior year, continued momentum in existing specialties (record July cases), and typical channel/insurance tailwinds. Stated overall market penetration is "very, very low" with huge opportunity.

    “So when you think about the gout expansion, right, we've executed our largest rare disease sales force expansion and we've increased our reps by 50%. This expansion from 120 to 180 reps, right? So that's a meaningful expansion. That expansion was operational by the end of June. I already spoke about the leading indicators of demand. So we expect Q3 to keep building on this momentum and therefore Q4 will have significantly higher impact from the gout expansion.”

    asked by Vamil Divan · answered by Nikhil Lalwani

    2 min read6 chapters

    Detailed Narrative

    01

    Transformation to Rare Disease Company

    ANI is actively transforming into a leading rare disease company, with rare disease products expected to approach 60% of total revenues in 2026. This strategic shift is supported by the strong performance of Cortrophin Gel and ongoing investments in commercial expansion and potential inorganic growth opportunities. The company aims to create operational leverage in 2027 and beyond from these investments.

    02

    Cortrophin Gel Growth and Gout Expansion

    Cortrophin Gel revenues grew 43% year-over-year and 56% quarter-over-quarter in Q2 FY26, driven by existing specialties. The company completed its largest rare disease sales force expansion, increasing reps by 50% to approximately 180, specifically targeting acute gouty arthritis flares in podiatry and primary care settings. Early indicators for the gout expansion are positive, with strong demand generation and high engagement from new sales representatives and prescribers.

    03

    Generics Business Performance

    The generics business delivered $99.1 million in revenue, up 10% year-over-year, driven by a partner generic launch, new product introductions, and operational execution. ANI launched 12 generics in 2026 and is on track for at least 15 for the full year, maintaining its position as the #2 player in CGT filings. Approximately 95% of generics revenues come from US-manufactured finished goods.

    04

    ILUVIEN and Retina Franchise

    ILUVIEN generated $18.7 million in Q2 revenue. The company reported top-line results from the Phase 4 SYNCHRONICITY trial in non-infectious uveitis of the posterior segment (NIU-PS) and plans to unveil detailed results at a medical conference in Q4 2026. Management believes the addressable patient populations in DME and NIU-PS represent at least 10x the number of patients currently treated, indicating significant long-term opportunity.

    05

    Capital Allocation Strategy

    ANI is focused on disciplined capital allocation, prioritizing organic growth investments like the Cortrophin commercial expansion and deploying a high single-digit percentage of generics revenue into R&D. The company is also evaluating inorganic growth opportunities for its rare disease business, seeking commercial or near-commercial assets synergistic with existing call points or infrastructure.

    06

    Market Penetration and Growth Runway

    The overall ACTH market is healthy, expected to grow nearly 30% to over $1.3 billion in 2026. Cortrophin Gel is expected to grow 50-55% within this market. Management estimates almost 1 million addressable patients across Cortrophin indications, with current ACTH therapies being vastly underpenetrated, suggesting a significant multi-year growth runway.

    AI-generated summary of the company’s earnings call. Not investment advice.